AAPL   318.86 (+-0.01%)
MSFT   182.79 (-0.39%)
FB   235.93 (+0.43%)
GOOGL   1,432.61 (+1.37%)
AMZN   2,433.45 (-0.14%)
NVDA   352.35 (-2.41%)
CGC   20.40 (+4.99%)
BABA   203.58 (+1.94%)
MU   45.92 (+2.04%)
GE   6.84 (+6.55%)
TSLA   817.11 (+0.03%)
AMD   54.54 (-1.14%)
T   30.95 (+3.58%)
ACB   15.98 (-0.25%)
GILD   73.84 (+0.68%)
DIS   121.43 (+2.89%)
NFLX   417.45 (-2.76%)
BAC   24.12 (+6.44%)
BA   143.87 (+4.61%)
AAPL   318.86 (+-0.01%)
MSFT   182.79 (-0.39%)
FB   235.93 (+0.43%)
GOOGL   1,432.61 (+1.37%)
AMZN   2,433.45 (-0.14%)
NVDA   352.35 (-2.41%)
CGC   20.40 (+4.99%)
BABA   203.58 (+1.94%)
MU   45.92 (+2.04%)
GE   6.84 (+6.55%)
TSLA   817.11 (+0.03%)
AMD   54.54 (-1.14%)
T   30.95 (+3.58%)
ACB   15.98 (-0.25%)
GILD   73.84 (+0.68%)
DIS   121.43 (+2.89%)
NFLX   417.45 (-2.76%)
BAC   24.12 (+6.44%)
BA   143.87 (+4.61%)
AAPL   318.86 (+-0.01%)
MSFT   182.79 (-0.39%)
FB   235.93 (+0.43%)
GOOGL   1,432.61 (+1.37%)
AMZN   2,433.45 (-0.14%)
NVDA   352.35 (-2.41%)
CGC   20.40 (+4.99%)
BABA   203.58 (+1.94%)
MU   45.92 (+2.04%)
GE   6.84 (+6.55%)
TSLA   817.11 (+0.03%)
AMD   54.54 (-1.14%)
T   30.95 (+3.58%)
ACB   15.98 (-0.25%)
GILD   73.84 (+0.68%)
DIS   121.43 (+2.89%)
NFLX   417.45 (-2.76%)
BAC   24.12 (+6.44%)
BA   143.87 (+4.61%)
AAPL   318.86 (+-0.01%)
MSFT   182.79 (-0.39%)
FB   235.93 (+0.43%)
GOOGL   1,432.61 (+1.37%)
AMZN   2,433.45 (-0.14%)
NVDA   352.35 (-2.41%)
CGC   20.40 (+4.99%)
BABA   203.58 (+1.94%)
MU   45.92 (+2.04%)
GE   6.84 (+6.55%)
TSLA   817.11 (+0.03%)
AMD   54.54 (-1.14%)
T   30.95 (+3.58%)
ACB   15.98 (-0.25%)
GILD   73.84 (+0.68%)
DIS   121.43 (+2.89%)
NFLX   417.45 (-2.76%)
BAC   24.12 (+6.44%)
BA   143.87 (+4.61%)
Log in

NASDAQ:REPHRecro Pharma Stock Price, Forecast & News

$4.72
-0.05 (-1.05 %)
(As of 05/26/2020 12:28 PM ET)
Add
Compare
Today's Range
$4.71
Now: $4.72
$4.95
50-Day Range
$4.34
MA: $7.18
$8.85
52-Week Range
$4.15
Now: $4.72
$19.21
Volume230,183 shs
Average Volume958,074 shs
Market Capitalization$111.25 million
P/E Ratio23.60
Dividend YieldN/A
Beta0.87
Recro Pharma, Inc., a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain. The company also develops early-stage product candidates, which include Dex-IN, an intranasal formulation of dexmedetomidine for use in clinical sedation; and two novel neuromuscular blocking agents and a related proprietary chemical reversal agent. In addition, it provides formulation and development services to develop and manufacture pharmaceutical products using proprietary delivery technologies and know-how for commercial partners. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.
Read More
Recro Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.67 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:REPH
CUSIPN/A
Phone484-395-2470

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$99.22 million
Cash Flow$0.57 per share
Book Value($0.30) per share

Profitability

Net Income$-18,630,000.00

Miscellaneous

Employees255
Market Cap$111.25 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive REPH News and Ratings via Email

Sign-up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter.

Recro Pharma (NASDAQ:REPH) Frequently Asked Questions

How has Recro Pharma's stock been impacted by COVID-19 (Coronavirus)?

Recro Pharma's stock was trading at $9.17 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, REPH shares have decreased by 48.5% and is now trading at $4.72. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Recro Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recro Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Recro Pharma.

When is Recro Pharma's next earnings date?

Recro Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Recro Pharma.

How were Recro Pharma's earnings last quarter?

Recro Pharma Inc (NASDAQ:REPH) issued its quarterly earnings data on Monday, May, 11th. The specialty pharmaceutical company reported ($0.33) EPS for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.30. The specialty pharmaceutical company earned $21.78 million during the quarter, compared to analyst estimates of $19.40 million. Recro Pharma had a negative return on equity of 15.25% and a negative net margin of 25.38%. View Recro Pharma's earnings history.

What guidance has Recro Pharma issued on next quarter's earnings?

Recro Pharma issued an update on its FY 2020 Pre-Market earnings guidance on Monday, May, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $80-85 million, compared to the consensus revenue estimate of $98.26 million.

What price target have analysts set for REPH?

2 equities research analysts have issued twelve-month price targets for Recro Pharma's stock. Their forecasts range from $12.00 to $18.00. On average, they anticipate Recro Pharma's share price to reach $15.00 in the next year. This suggests a possible upside of 217.8% from the stock's current price. View analysts' price targets for Recro Pharma.

Has Recro Pharma been receiving favorable news coverage?

Media headlines about REPH stock have been trending somewhat positive on Tuesday, according to InfoTrie. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Recro Pharma earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave media stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutRecro Pharma.

Are investors shorting Recro Pharma?

Recro Pharma saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,230,000 shares, an increase of 5.1% from the April 30th total of 1,170,000 shares. Based on an average daily volume of 500,800 shares, the short-interest ratio is currently 2.5 days. Approximately 6.2% of the company's shares are sold short. View Recro Pharma's Current Options Chain.

Who are some of Recro Pharma's key competitors?

What other stocks do shareholders of Recro Pharma own?

Who are Recro Pharma's key executives?

Recro Pharma's management team includes the following people:
  • Dr. Geraldine A. Henwood, Pres, CEO & Director (Age 67)
  • Mr. Ryan D. Lake, Chief Financial Officer (Age 42)
  • Mr. Michael Celano, COO & Corp. Sec. (Age 60)
  • Mr. Randall J. Mack, Sr. VP of Devel. & Corp. Sec. (Age 54)
  • Ms. Diane Myers, Sr. VP of Regulatory Affairs & Quality Assurance (Age 55)

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

Who are Recro Pharma's major shareholders?

Recro Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.72%), Federated Hermes Inc. (1.77%), State Street Corp (1.76%), Mak Capital One LLC (1.65%), Corsair Capital Management L.P. (1.56%) and Nuveen Asset Management LLC (1.55%). Company insiders that own Recro Pharma stock include Arnaud Ajdler and Geraldine Henwood. View institutional ownership trends for Recro Pharma.

Which major investors are selling Recro Pharma stock?

REPH stock was sold by a variety of institutional investors in the last quarter, including Corsair Capital Management L.P., Two Sigma Investments LP, Driehaus Capital Management LLC, Parametric Portfolio Associates LLC, Russell Investments Group Ltd., Squarepoint Ops LLC, JPMorgan Chase & Co., and Hillsdale Investment Management Inc.. View insider buying and selling activity for Recro Pharma.

Which major investors are buying Recro Pharma stock?

REPH stock was acquired by a variety of institutional investors in the last quarter, including Mak Capital One LLC, GW&K Investment Management LLC, Wells Fargo & Company MN, Roubaix Capital LLC, Nuveen Asset Management LLC, Private Advisors LLC, Two Sigma Advisers LP, and Deutsche Bank AG. View insider buying and selling activity for Recro Pharma.

How do I buy shares of Recro Pharma?

Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Recro Pharma's stock price today?

One share of REPH stock can currently be purchased for approximately $4.72.

How big of a company is Recro Pharma?

Recro Pharma has a market capitalization of $111.25 million and generates $99.22 million in revenue each year. The specialty pharmaceutical company earns $-18,630,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Recro Pharma employs 255 workers across the globe.

What is Recro Pharma's official website?

The official website for Recro Pharma is www.recropharma.com.

How can I contact Recro Pharma?

Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2470 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.